The approval of Wakix marks the first time a non-routine treatment option has been approved for excessive daytime sleepiness in patients aged 6 years and older.
The approval of Wakix marks the first time a non-routine treatment option has been approved for excessive daytime sleepiness in patients aged 6 years and older.
Sign in to your account